Teleflex to Acquire Palette Life Sciences for ~$650M
Shots:
- Teleflex to acquire Palette Life Sciences AB for an up front cash fee of $600M & an additional ~$50M upon achievement of commercial milestones. The acquisition is expected to be close in Q4’23
- The acquisition will expand the Teleflex Interventional Urology portfolio incl. UroLift System with the addition of non-animal stabilized hyaluronic acid (NASHA) spacer & tissue bulking products improves patient outcomes in urology & urogynecology disorders, colorectal conditions & radiation oncology procedures
- The Palette Life Sciences portfolio also includes Deflux & Solesta designed to treat pediatric vesicoureteral reflux and fecal incontinence, respectively. Barrigel was cleared for marketing in the US, and Australia, and is CE Marked
Ref: GlobeNewswire | Image: Palette
Related News:- Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
